Acute Pulmonary Embolism
Conditions
Brief summary
From January 1, 2023 to December 30, 2023, patients who were suspected of pulmonary embolism and underwent CTPA examination at Nanyang Hospital of Southern Medical University were divided into pulmonary embolism group and non pulmonary embolism group. 1. Collect relevant data, including gender, age, primary disease, CTPA imaging and reports, BNP, troponin, electrocardiogram, cardiac ultrasound, PT, APTT, TT, fibrinogen, D-dimer, etc., and analyze demographic data, pulmonary embolism risk grading, APTT/fibrinogen ratio, and determine their cut-off values through statistical analysis of the two groups. 2. Follow up on the APTT/fibrinogen ratio after anticoagulation treatment and bleeding in the pulmonary embolism group.
Interventions
DIAGNOSTIC_TEST2018 edition of the Guidelines for Diagnosis
According to the 2018 edition of the Guidelines for Diagnosis, Treatment and Prevention of Pulmonary Thromboembolism, and based on inclusion and exclusion criteria, enrolled patients were divided into a pulmonary embolism group and a non pulmonary embolism group
Sponsors
Nanfang Hospital, Southern Medical University
Shenzhen Nanshan Hospital
Ganzhou City People's Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
1. Voluntary signing of informed consent form; 2. When signing the informed consent form, the age is equal to or greater than 18 years old, regardless of gender; 3. From January 1, 2023 to December 30, 2023, the patient was diagnosed with suspected pulmonary embolism at the Southern Hospital of Southern Medical University and underwent enhanced pulmonary artery scanning examination.
Exclusion criteria
1. Patients with gastrointestinal bleeding, severe trauma, acute coronary syndrome, severe liver disease (childC grade), and coagulation dysfunction; 2. Patients with pulmonary embolism diagnosed outside the hospital and regular anticoagulation; 3. Patients undergoing regular anticoagulant therapy such as atrial fibrillation and valve replacement; 4. Patients deemed unsuitable for participation in this study by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cutoff value of APTT/FIB between patients with and without acute pulmonary embolism | 2024.01-2026.12 |
Countries
China
Outcome results
None listed